Abstract 2245
Background
Cancer care costs are a major concern for patients and society. We aimed to assess real life costs for the medical management of uMM.
Methods
We performed a retrospective patient chart review collecting data on demographics, disease characteristics and management. A complete registry of patients diagnosed with melanoma at the Antwerp University Hospital between 2007 and 12/2017 was compiled. Eligible for this chart review were all patients with uMM with sufficient data available and who either had an observation period of > 1 year at the time of this review or who deceased before December 31, 2017. Direct costs were calculated by multiplying each item of resource use, obtained from each individual patient chart, with its unit cost (2018, €) using the Belgian public health care payer’s perspective (PHCP) and patient’s perspective. A Kaplan–Meier sample average (KMSA) estimator was used to weight expected costs by the probability of survival and to adjust for censored data.
Results
89 patients fulfilled all eligibility criteria for this chart review. Ten of the patients (11%) are still alive. 9 patients (10%) received best supportive care (BSC) only. 40 patients (45%) received > 1 immunotherapy or targeted agent. Mean overall monthly cost/patient for the entire cohort was € 7,244, of which € 7,153 was covered by the public health care payer. The cost was driven by systemic treatment costs (69% of cost). Median overall survival (OS) was 8.18 months (95 % CI: 6.0-10.3). Mean monthly overall cost was € 9,269 for patients (n = 40) with potential access to anti-PD1, anti-CTLA-4, BRAFi, and MEKi; median OS in this cohort was 13.83 months (95 % CI: 8.6-19.0). Mean monthly overall cost was € 3,258 for patients (n = 33) treated with chemotherapy/BSC only. Median OS in this cohort was 3.91 months (95 % CI: 2.2-5.6). Mean monthly overall cost was € 5,398 for patients (n = 16) who had access to anti-CTLA-4 and/or BRAFi but not to MEKi and anti-PD1. Median OS in these patients was 11.0 months (95 % CI 7.5-14.6).
Conclusions
Management of uMM results in considerable costs for the PHCP, mainly driven by systemic treatment costs. Also in a real-life setting, the introduction of immunotherapy and targeted agents substantially improved survival. However, mean monthly cost has nearly tripled.
Clinical trial identification
Legal entity responsible for the study
Antwerp University Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1978 - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer.
Presenter: Kiyoshi Saeki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3682 - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3319 - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma
Presenter: Min Hee Hong
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5130 - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma
Presenter: Myung-Won Lee
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4483 - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis
Presenter: Thomas Mrowiec
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1175 - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis.
Presenter: Naoko Sato
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1359 - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors
Presenter: Miriam López Gómez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2651 - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells
Presenter: Kohei Morita
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2233 - Somatic-stem transition of tumor cells is a key link in the metastasis
Presenter: Nicolai Litviakov
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2601 - Profile of individuals who never undergo colorectal cancer screening
Presenter: Jérôme Viguier
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract